MX2022003291A - Vectores de adn sinteticos y metodos de uso. - Google Patents

Vectores de adn sinteticos y metodos de uso.

Info

Publication number
MX2022003291A
MX2022003291A MX2022003291A MX2022003291A MX2022003291A MX 2022003291 A MX2022003291 A MX 2022003291A MX 2022003291 A MX2022003291 A MX 2022003291A MX 2022003291 A MX2022003291 A MX 2022003291A MX 2022003291 A MX2022003291 A MX 2022003291A
Authority
MX
Mexico
Prior art keywords
dna vectors
methods
dna
synthetic dna
subject
Prior art date
Application number
MX2022003291A
Other languages
English (en)
Inventor
Bruce C Schnepp
Philip R Johnson
Original Assignee
Intergalactic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intergalactic Therapeutics Inc filed Critical Intergalactic Therapeutics Inc
Publication of MX2022003291A publication Critical patent/MX2022003291A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Abstract

Se proporciona en la presente vectores de ADN aislados que comprenden un gen heterólogo, en donde el vector de ADN está desprovisto de ADN plasmídico bacteriano y/o firmas bacterianas, que pueden anular la persistencia in vivo. La invención también presenta composiciones farmacéuticas (composiciones farmacéuticas no inmunogénicas) incluido los vectores de ADN de la invención, que se pueden usar para inducción de la expresión episomática a largo plazo de un gen heterólogo en un sujeto. La invención implica métodos para tratar un sujeto al administrar los vectores de ADN de la invención, incluidos métodos para tratar trastornos asociados con un defecto en un gen objetivo.
MX2022003291A 2019-09-18 2020-09-18 Vectores de adn sinteticos y metodos de uso. MX2022003291A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962902084P 2019-09-18 2019-09-18
PCT/US2020/051507 WO2021055760A1 (en) 2019-09-18 2020-09-18 Synthetic dna vectors and methods of use

Publications (1)

Publication Number Publication Date
MX2022003291A true MX2022003291A (es) 2022-09-09

Family

ID=74884687

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003291A MX2022003291A (es) 2019-09-18 2020-09-18 Vectores de adn sinteticos y metodos de uso.

Country Status (12)

Country Link
US (6) US20210330817A1 (es)
EP (1) EP4031168A4 (es)
JP (1) JP2022549138A (es)
KR (1) KR20220128607A (es)
CN (1) CN115066255A (es)
AU (1) AU2020351204A1 (es)
CA (1) CA3151464A1 (es)
GB (1) GB2606844A (es)
IL (1) IL291437A (es)
MX (1) MX2022003291A (es)
TW (1) TW202124722A (es)
WO (1) WO2021055760A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019233901A1 (en) * 2018-03-15 2020-09-17 Intergalactic Therapeutics, Inc. Synthetic DNA vectors and methods of use
CN116479022A (zh) * 2018-12-12 2023-07-25 中南大学 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
GB2606844A (en) 2019-09-18 2022-11-23 Intergalactic Therapeutics Inc Synthetic DNA vectors and methods of use
EP4288553A1 (en) * 2021-02-02 2023-12-13 University of Massachusetts Inverted terminal repeats from aav serotypes 8 and rh.39 in gene therapy vectors
WO2023049937A2 (en) * 2021-09-27 2023-03-30 Intergalactic Therapeutics, Inc. Synthetic production of circular dna vectors
WO2023064934A1 (en) * 2021-10-15 2023-04-20 Intergalactic Therapeutics, Inc. Respiratory delivery of therapeutic agents
WO2023122625A2 (en) * 2021-12-20 2023-06-29 Intergalactic Therapeutics, Inc. Production of gene therapy vector in engineered bacteria

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2488641A (en) * 1947-06-17 1949-11-22 Herschel V Seawright Revolving display rack for showcases
US6027722A (en) 1990-10-25 2000-02-22 Nature Technology Corporation Vectors for gene transfer
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
FR2731014B1 (fr) 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US7030098B2 (en) 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
NZ515645A (en) 1999-05-28 2004-07-30 Cambrex Bio Science Baltimore Methods of purifying plasmid DNA mixture containing host cell impurities
WO2002020814A1 (en) 2000-09-08 2002-03-14 The General Hospital Corporation Self-rearranging dna vectors
US20070196838A1 (en) 2000-12-08 2007-08-23 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20030082559A1 (en) 2001-01-19 2003-05-01 David Beach Methods and reagents for amplification and manipulation of vector and target nucleic acid sequences
FR2821855B1 (fr) * 2001-03-09 2004-04-02 Cayla Genes synthetiques et plasmides bacteriens depourvus de cpg
RU2005106999A (ru) 2002-08-29 2005-08-27 Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити (Us) Кольцевые векторы нуклеиновой кислоты и способы их создания и использования
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
US20050069991A1 (en) * 2003-03-25 2005-03-31 Hyman Edward D. Method for plasmid preparation by conversion of open circular plasmid to supercoiled plasmid
AT412400B (de) 2003-05-08 2005-02-25 Mayrhofer Peter Mag Dr Minicircle-herstellung
US8802643B1 (en) 2003-05-30 2014-08-12 University Of South Florida Method for the treatment of malignancies
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
EP1781800B1 (en) 2004-08-19 2013-06-19 Nature Technology Corp. Process for plasmid dna fermentation
US20080305142A1 (en) 2004-12-11 2008-12-11 Cytogenix, Inc. Cell Free Biosynthesis of High-Quality Nucleic Acid and Uses Thereof
US7622252B2 (en) 2005-06-10 2009-11-24 Baylor College Of Medicine Generation of minicircle DNA with physiological supercoiling
WO2007018744A2 (en) 2005-08-03 2007-02-15 Cytogenix, Inc. Cell-free biosynthesis of nucleic acid
US20080318283A1 (en) 2006-02-01 2008-12-25 Clague P. Hodgson Fermentation Process for Continuous Plasmid Dna Production
US9017966B2 (en) 2007-05-23 2015-04-28 Nature Technology Corporation E. coli plasmid DNA production
US9109012B2 (en) 2007-05-29 2015-08-18 Nature Technology Corporation Vectors and method for genetic immunization
EP2262899A1 (en) 2008-04-02 2010-12-22 Fondazione Telethon Method of treating genetic disorders
US8945885B2 (en) 2008-07-03 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
US8921072B2 (en) 2008-09-02 2014-12-30 General Electric Compnay Methods to generate DNA mini-circles
US9045759B2 (en) 2009-01-21 2015-06-02 James Arthur Williams DNA plasmids with improved copy number
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
EP2488641B1 (en) 2009-10-16 2019-01-23 Baylor College Of Medicine Supercoiled minicircle dna for gene therapy applications
US9506082B2 (en) 2010-04-12 2016-11-29 Nature Technology Corporation Eukaryotic expression vectors resistant to transgene silencing
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
EP2439276A1 (de) * 2010-10-05 2012-04-11 Rentschler Biotechnologie GmbH Verfahren zur semi-synthetischen Herstellung hochreiner "MiniCircle" DNA-Vektoren aus Plasmiden
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
EA026926B1 (ru) 2011-12-12 2017-05-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Композиции, содержащие улучшенные генетические конструкции il-12, вакцины, иммунотерапевтические составы и способы их применения
WO2013119371A2 (en) 2012-02-10 2013-08-15 The Board Of Trustees Of The Leland Stanford Junior University Mini-intronic plasmid vectors
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
US20140056868A1 (en) 2012-05-30 2014-02-27 University of Washington Center for Commercialization Supercoiled MiniVectors as a Tool for DNA Repair, Alteration and Replacement
WO2014077863A1 (en) 2012-11-19 2014-05-22 Nature Technology Corporation Replicative minicircle vectors with improved expression
MX2015007575A (es) 2012-12-13 2016-03-15 Univ Pennsylvania Construcciones de anticuerpos de adn y metodo para utilizarlas.
US9701981B2 (en) 2013-03-15 2017-07-11 The Board Of Trustees Of The Leland Stanford Junior University Nucleosome-excluding sequences (NES) as a DNA spacer in vectors results in prolonged transgene expression in eukaryotic cells
GB201307075D0 (en) 2013-04-19 2013-05-29 Mayrhofer Peter Plasmid for minicircle production
CA2910427C (en) 2013-05-10 2024-02-20 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
CN104342453A (zh) 2013-08-06 2015-02-11 深圳先进技术研究院 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
US9827308B2 (en) 2014-12-10 2017-11-28 Wisconsin Alumni Research Foundation Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade
CN107208102B (zh) * 2015-01-27 2021-07-06 豪夫迈·罗氏有限公司 重组hbv cccdna、其产生方法及其用途
WO2016126987A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Compositions and methods for synthetic gene assembly
DK3286311T3 (da) 2015-03-26 2021-05-17 Oncosec Medical Inc Fremgangsmåde til behandling af maligniteter
AU2016260401B2 (en) 2015-05-14 2022-05-19 St. Jude Children's Research Hospital, Inc. Nucleic acid molecules containing spacers and methods of use thereof
WO2017050884A1 (en) * 2015-09-22 2017-03-30 Julius-Maximilians-Universität Würzburg A method for high level and stable gene transfer in lymphocytes
WO2017087900A1 (en) 2015-11-19 2017-05-26 The Trustees Of The University Of Pennsylvania Compositions and methods for correction of heritable ocular disease
SG11201805162VA (en) 2015-12-18 2018-07-30 Oncosec Medical Inc Plasmid constructs for heterologous protein expression and methods of use
EP3205356A1 (en) 2016-02-10 2017-08-16 Onkoloski Institut Ljubljana Plasmid expression vector encoding human interleukin 12 under transcriptional control of p21 promoter and without antibiotic resistance for cancer gene therapy and other uses thereof
CN109195636B (zh) 2016-03-03 2022-07-05 马萨诸塞大学 用于非病毒基因转移的末端封闭型线性双链体dna
US10077459B2 (en) 2016-05-04 2018-09-18 General Electric Company Cell-free protein expression using rolling circle amplification product
US11060137B2 (en) 2016-12-14 2021-07-13 Codex Dna, Inc. Methods for assembling DNA molecules
RU2752611C2 (ru) 2017-02-28 2021-07-29 Орикиро Дженомикс, Инк. Способ репликации или амплификации кольцевой днк
US20180305701A1 (en) * 2017-03-14 2018-10-25 Baylor College Of Medicine Targeting minivectors to specific tissue using shape
AU2018238422A1 (en) 2017-03-21 2019-10-03 Martin Biel Gene therapy for the treatment of CNGB1-linked retinitis pigmentosa
EP3606544A4 (en) 2017-04-05 2021-04-07 University of Massachusetts MINI-GENE THERAPY
CN108728465A (zh) 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
US20200123566A1 (en) 2017-06-13 2020-04-23 Oncosec Medical Incorporated Multigene construct for immune-modulatory protein expression and methods of use
CN110914414A (zh) * 2017-06-14 2020-03-24 德累斯顿工业大学 利用设计dna重组酶遗传改变基因组的方法与手段
MA50100A (fr) * 2017-09-08 2020-07-15 Generation Bio Co Adn à extrémité fermée (cedna) modifié
WO2019057774A1 (en) 2017-09-19 2019-03-28 Deutsches Krebsforschungszentrum NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS
DK3456821T4 (da) 2017-09-19 2024-04-15 Deutsches Krebsforsch Ikke-integrerende dna-vektorer til genetisk modifikation af celler
US20200048716A1 (en) 2017-11-03 2020-02-13 Twister Biotech, Inc Using minivectors to treat ovarian cancer
AU2019233901A1 (en) * 2018-03-15 2020-09-17 Intergalactic Therapeutics, Inc. Synthetic DNA vectors and methods of use
JP2021518150A (ja) 2018-03-21 2021-08-02 ネイチャー テクノロジー コーポレーション 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター
MA52709A (fr) 2018-05-23 2021-03-31 Modernatx Inc Administration d'adn
WO2020077159A1 (en) 2018-10-10 2020-04-16 The Johns Hopkins University POLY(Beta-AMINO ESTER) NANOPARTICLES FOR THE NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINAL GENE THERAPY
WO2020101828A2 (en) 2018-10-12 2020-05-22 Children's Hospital Medical Center Modular expression systems for gene expression and methods of using same
US20210383891A1 (en) 2018-10-19 2021-12-09 New England Biolabs, Inc. Improved Ordered Assembly of Multiple DNA Fragments
CN109402168A (zh) 2018-10-30 2019-03-01 深圳新诺微环生物科技有限公司 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用
TW202039537A (zh) 2018-11-27 2020-11-01 美商昂科賽克醫療公司 用於治療癌症之質體建構體和使用方法
CN111378677A (zh) 2018-12-27 2020-07-07 南京中科游子生物技术研究院有限公司 一种dna组装的方法及其应用
US20220090090A1 (en) 2019-01-15 2022-03-24 University Of Marlyland, Baltimore County A method for assembling circular and linear dna molecules in an ordered manner
EP3931319A1 (en) 2019-02-28 2022-01-05 ProteoNic Biotechnology IP B.V. Self-immolative plasmid backbone
EP3956453A4 (en) 2019-04-19 2023-02-22 University of Massachusetts GENE THERAPIES FOR USHER SYNDROME (USH1B)
WO2020214796A1 (en) 2019-04-19 2020-10-22 University Of Massachusetts Gene therapies for usher syndrome (ush2a)
AU2020257392A1 (en) 2019-04-19 2021-11-18 University Of Massachusetts Gene therapies for Stargardt disease (ABCA4)
CN110564751A (zh) 2019-09-03 2019-12-13 深圳新诺微环生物科技有限公司 微环dna疫苗设计及应用
CN110684798A (zh) 2019-09-03 2020-01-14 深圳新诺微环生物科技有限公司 肌肉靶向的微环dna基因治疗
GB2606844A (en) 2019-09-18 2022-11-23 Intergalactic Therapeutics Inc Synthetic DNA vectors and methods of use

Also Published As

Publication number Publication date
US20210330817A1 (en) 2021-10-28
EP4031168A1 (en) 2022-07-27
WO2021055760A1 (en) 2021-03-25
AU2020351204A1 (en) 2022-04-21
US20230270888A1 (en) 2023-08-31
GB202204355D0 (en) 2022-05-11
US20220168451A1 (en) 2022-06-02
CA3151464A1 (en) 2021-03-25
TW202124722A (zh) 2021-07-01
EP4031168A4 (en) 2023-10-11
GB2606844A (en) 2022-11-23
US11324839B2 (en) 2022-05-10
US20210322576A1 (en) 2021-10-21
JP2022549138A (ja) 2022-11-24
US20210322579A1 (en) 2021-10-21
US11602569B2 (en) 2023-03-14
IL291437A (en) 2022-05-01
US20230089543A1 (en) 2023-03-23
US11766490B2 (en) 2023-09-26
KR20220128607A (ko) 2022-09-21
US11684680B2 (en) 2023-06-27
CN115066255A (zh) 2022-09-16

Similar Documents

Publication Publication Date Title
MX2022003291A (es) Vectores de adn sinteticos y metodos de uso.
MX2020009579A (es) Vectores de adn sintetico y metodos de uso.
MX2022004786A (es) Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular.
EP4241784A3 (en) Artificial nucleic acid molecules for improved protein expression
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
AU2017234929B2 (en) Therapeutic for treatment of diseases including the central nervous system
WO2016109546A3 (en) Methods and compositions for prognosis and treatment of cancers
MX2021004282A (es) Construcciones de ácido nucleico y métodos de uso.
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
EP4310500A3 (en) Methods and compositons for the activation of gamma-delta t-cells
MX2021006730A (es) Citomegalovirus humano compuesto por antigenos exogenos.
WO2019094791A3 (en) Targeted crispr delivery platforms
MX2019006426A (es) Reguladores de tau, y composiciones y metodos para su administracion.
MX2022006602A (es) Vacunas de herpesvirus de pavo recombinante y uso de las mismas.
WO2019226939A8 (en) Immune checkpoint inhibitor co-expression vectors
MX2020009736A (es) Composiciones que comprenden cepas bacterianas.
MX2021013913A (es) Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa.
MX2021009696A (es) Vectores de genoterapia para el tratamiento de la enfermedad de danon.
EP4079750A3 (en) Adenoviruses and methods for using adenoviruses
MX2021002041A (es) Terapia génica para el tratamiento de galactosemia.
PH12020551191A1 (en) Oligodendrocyte-specific promoter, mirna specific to plp1 gene, vector including said promoter and/or mirna, and pharmaceutical composition including said vector
MX2021011958A (es) Terapias genicas para trastornos lisosomales.
PH12018501183A1 (en) Method of preparing porcine circovirus type 2 capsid protein and pharmaceutical composition comprising same
MX2017016625A (es) Induccion de la expresion genica usando una mezcla de azucar de alta concentracion.
WO2019046341A3 (en) Methods and compositions for treating cone-rod retinal dystrophy